Clinical trial · no report yet · Phase 1/Phase 2
NEXICART-2
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
- NCT06097832 ↗
- Active not recruiting
- Nexcella Inc.
- 14 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| YouTube | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis
- Phase
- Phase 1/Phase 2
- Status
- Active not recruiting
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- NXC-201 CAR-T
- Arms
- NXC-201 CAR-T · Experimental
- Enrollment
- 45 (estimated)
- Primary outcomes
- Number of Participants With Treatment-Related Adverse Events
- Number of Participants with Adverse Events by Severity as Assessed by CTCAE v5.0
- To confirm the maximum tolerated dose (MTD)
- To confirm the recommended phase 2 dose (RP2D)
- Sponsor
- Nexcella Inc. with Immix Biopharma, Inc.
- Start
- Jun 5, 2024
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06097832 · updated Jul 14, 2026
Publications
linked from the registry- Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, Sharon TD, Pick M, Lebel E, Shaulov A, Cohen YC, Avivi I, Cohen CJ, Stepensky P, Gatt ME. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PubMed 36107221
- Asherie N, Kfir-Erenfeld S, Avni B, Assayag M, Dubnikov T, Zalcman N, Lebel E, Zimran E, Shaulov A, Pick M, Cohen Y, Avivi I, Cohen C, Gatt ME, Grisariu S, Stepensky P. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628. PubMed 36200421
- Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22. PubMed 23091105
- Al Haddad N, Brailovski E, Dela-Pena J, Cook M, Rosenzweig M, Jolie Landau H. BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma. EJHaem. 2026 Jun 16;7(3):e70329. doi: 10.1002/jha2.70329. eCollection 2026 Jun. PubMed 42312318